| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C0013185> <https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C1615608> <https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C5387588> <https://research.tib.eu/covid-19/entity/35129827_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Exon Consultancy, Amsterdam, The Netherlands. kevin@exon-consultancy.nl.\', \'Exon Consultancy, Amsterdam, The Netherlands.\', \'European Federation of Pharmaceutical Industries and Associations (EFPIA), Ixelles, Belgium.\', \'MSD, London, UK.\', \'Bayer PLC, Reading, UK.\', \'Bayer AG, Wuppertal, Germany.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Acha_Virginia> <https://research.tib.eu/covid-19/entity/Klein_Kevin> <https://research.tib.eu/covid-19/entity/Montagne_Sarah> <https://research.tib.eu/covid-19/entity/St%C3%B6ckert_Isabelle> <https://research.tib.eu/covid-19/entity/Stolk_Pieter> <https://research.tib.eu/covid-19/entity/Tellner_P%C3%A4r>
?:doi	<https://research.tib.eu/covid-19/entity/10.1007/s43441-022-00383-3>
?:doi	10.1007/s43441-022-00383-3
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Research_Support%2C_Non-U.S._Gov%27t>
?:journal	Therapeutic innovation & regulatory science
is ?:pmid of	<https://research.tib.eu/covid-19/entity/35129827>
?:pmid	<https://research.tib.eu/covid-19/entity/35129827>
?:pmid	35129827
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	-1.0
?:rankingScore_hIndex	-1
?:title	Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2022

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/35129827>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/35129827>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all